GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Rhea-AI Summary

GeoVax Labs, Inc. (GOVX) will report its 2023 financial results on February 29, 2024, after U.S. markets close. The company, a clinical-stage biotechnology firm, specializes in developing immunotherapies and vaccines for cancer and infectious diseases. A live conference call and webcast will follow the financial report for a corporate update and Q&A session.

GeoVax to Host Conference Call at 4:30 PM ET

ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2023 financial results on Thursday, February 29, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.

Dial-in numbers:

Domestic:          (800) 715-9871
International:    +1 (646) 307-1963
Conference ID:  3926207

Webcast:
A webcast of the live call may be accessed here and on the Events page of the GeoVax website. A webcast replay of the call will be available for three months via the same link as the live webcast approximately two hours after the end of the call.

About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Company Contact:		Investor Relations Contact:		Media Contact:
info@geovax.com		paige.kelly@sternir.com		sr@roberts-communications.com
678-384-7220		212-698-8699		202-779-0929

When will GeoVax Labs, Inc. (GOVX) report its 2023 financial results?

GeoVax Labs, Inc. (GOVX) will report its 2023 financial results on Thursday, February 29, 2024, after the close of U.S. markets.

What does GeoVax Labs, Inc. (GOVX) specialize in?

GeoVax Labs, Inc. (GOVX) is a clinical-stage biotechnology company that focuses on developing immunotherapies and vaccines for cancer and infectious diseases.

When is the conference call and webcast scheduled?

The live conference call and webcast, including Q&A, will be held at 4:30 p.m. ET on the same day as the financial results report, February 29, 2024.

How can one access the webcast of the conference call?

The webcast of the live call can be accessed on the Events page of the GeoVax website or through the provided webcast link.

Will there be a webcast replay available?

Yes, a webcast replay of the call will be available for three months via the same link as the live webcast, approximately two hours after the call ends.